Is CTSO or PYPD more profitable?

PolyPid has a net margin of 0.00% compared to Cytosorbents' net margin of -31.85%. Cytosorbents' return on equity of -235.57% beat PolyPid's return on equity. Company Net Margins Return on Equity Return on Assets Cytosorbents -31.85% -235.57% -37.88% PolyPid N/A -241.96% -126.91%

Cytosorbents (CTSO) Competitors

$0.37 +0.01 (+2.49%)

As of 10:52 AM Eastern

Compare

CTSO vs. VANI, LAKE, PYPD, SPAI, and INO

Should you buy Cytosorbents stock or one of its competitors? MarketBeat compares Cytosorbents with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cytosorbents include Vivani Medical (VANI), Lakeland Industries (LAKE), PolyPid (PYPD), Safe Pro Group (SPAI), and Inovio Pharmaceuticals (INO). These companies are all part of the "medical equipment" industry.

How does Cytosorbents compare to Vivani Medical?

Cytosorbents (NASDAQ:CTSO) and Vivani Medical (NASDAQ:VANI) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, earnings, analyst recommendations and dividends.

Vivani Medical has a net margin of 0.00% compared to Cytosorbents' net margin of -31.85%. Cytosorbents' return on equity of -235.57% beat Vivani Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytosorbents	-31.85%	-235.57%	-37.88%
Vivani Medical	N/A	-264.04%	-79.85%

Cytosorbents has a beta of 1.35, meaning that its share price is 35% more volatile than the broader market. Comparatively, Vivani Medical has a beta of 2.31, meaning that its share price is 131% more volatile than the broader market.

32.9% of Cytosorbents shares are held by institutional investors. Comparatively, 6.8% of Vivani Medical shares are held by institutional investors. 7.8% of Cytosorbents shares are held by company insiders. Comparatively, 53.3% of Vivani Medical shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Cytosorbents has higher revenue and earnings than Vivani Medical. Vivani Medical is trading at a lower price-to-earnings ratio than Cytosorbents, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytosorbents	$37.06M	0.63	-$8.20M	-$0.19	N/A
Vivani Medical	N/A	N/A	-$26.61M	-$0.40	N/A

Cytosorbents currently has a consensus price target of $5.38, indicating a potential upside of 1,348.79%. Vivani Medical has a consensus price target of $3.75, indicating a potential upside of 215.13%. Given Cytosorbents' higher probable upside, equities analysts plainly believe Cytosorbents is more favorable than Vivani Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytosorbents	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Vivani Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Vivani Medical had 5 more articles in the media than Cytosorbents. MarketBeat recorded 6 mentions for Vivani Medical and 1 mentions for Cytosorbents. Cytosorbents' average media sentiment score of 1.89 beat Vivani Medical's score of 0.70 indicating that Cytosorbents is being referred to more favorably in the media.

Company	Overall Sentiment
Cytosorbents	Very Positive
Vivani Medical	Positive

Summary

Cytosorbents beats Vivani Medical on 9 of the 15 factors compared between the two stocks.

How does Cytosorbents compare to Lakeland Industries?

Cytosorbents (NASDAQ:CTSO) and Lakeland Industries (NASDAQ:LAKE) are both small-cap medical equipment companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, institutional ownership, risk and profitability.

Cytosorbents has higher earnings, but lower revenue than Lakeland Industries. Lakeland Industries is trading at a lower price-to-earnings ratio than Cytosorbents, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytosorbents	$37.06M	0.63	-$8.20M	-$0.19	N/A
Lakeland Industries	$192.65M	0.57	-$25.31M	-$2.13	N/A

Lakeland Industries has a net margin of -10.87% compared to Cytosorbents' net margin of -31.85%. Lakeland Industries' return on equity of -6.64% beat Cytosorbents' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytosorbents	-31.85%	-235.57%	-37.88%
Lakeland Industries	-10.87%	-6.64%	-4.13%

32.9% of Cytosorbents shares are owned by institutional investors. Comparatively, 71.7% of Lakeland Industries shares are owned by institutional investors. 7.8% of Cytosorbents shares are owned by insiders. Comparatively, 3.4% of Lakeland Industries shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Cytosorbents currently has a consensus target price of $5.38, indicating a potential upside of 1,348.79%. Lakeland Industries has a consensus target price of $16.00, indicating a potential upside of 44.53%. Given Cytosorbents' higher possible upside, analysts plainly believe Cytosorbents is more favorable than Lakeland Industries.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytosorbents	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Lakeland Industries	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, Lakeland Industries had 4 more articles in the media than Cytosorbents. MarketBeat recorded 5 mentions for Lakeland Industries and 1 mentions for Cytosorbents. Cytosorbents' average media sentiment score of 1.89 beat Lakeland Industries' score of 0.44 indicating that Cytosorbents is being referred to more favorably in the media.

Company	Overall Sentiment
Cytosorbents	Very Positive
Lakeland Industries	Neutral

Cytosorbents has a beta of 1.35, indicating that its share price is 35% more volatile than the broader market. Comparatively, Lakeland Industries has a beta of 1.45, indicating that its share price is 45% more volatile than the broader market.

Summary

Lakeland Industries beats Cytosorbents on 9 of the 16 factors compared between the two stocks.

How does Cytosorbents compare to PolyPid?

Cytosorbents (NASDAQ:CTSO) and PolyPid (NASDAQ:PYPD) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, dividends, institutional ownership, profitability and valuation.

In the previous week, PolyPid had 2 more articles in the media than Cytosorbents. MarketBeat recorded 3 mentions for PolyPid and 1 mentions for Cytosorbents. Cytosorbents' average media sentiment score of 1.89 beat PolyPid's score of 0.68 indicating that Cytosorbents is being referred to more favorably in the media.

Company	Overall Sentiment
Cytosorbents	Very Positive
PolyPid	Positive

Cytosorbents has higher revenue and earnings than PolyPid. PolyPid is trading at a lower price-to-earnings ratio than Cytosorbents, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytosorbents	$37.06M	0.63	-$8.20M	-$0.19	N/A
PolyPid	N/A	N/A	-$34.17M	-$1.91	N/A

PolyPid has a net margin of 0.00% compared to Cytosorbents' net margin of -31.85%. Cytosorbents' return on equity of -235.57% beat PolyPid's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytosorbents	-31.85%	-235.57%	-37.88%
PolyPid	N/A	-241.96%	-126.91%

Cytosorbents currently has a consensus target price of $5.38, indicating a potential upside of 1,348.79%. PolyPid has a consensus target price of $11.67, indicating a potential upside of 134.51%. Given Cytosorbents' higher probable upside, equities research analysts clearly believe Cytosorbents is more favorable than PolyPid.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytosorbents	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
PolyPid	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Cytosorbents has a beta of 1.35, suggesting that its stock price is 35% more volatile than the broader market. Comparatively, PolyPid has a beta of 1.42, suggesting that its stock price is 42% more volatile than the broader market.

32.9% of Cytosorbents shares are owned by institutional investors. Comparatively, 26.5% of PolyPid shares are owned by institutional investors. 7.8% of Cytosorbents shares are owned by insiders. Comparatively, 24.7% of PolyPid shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Cytosorbents beats PolyPid on 9 of the 15 factors compared between the two stocks.

How does Cytosorbents compare to Safe Pro Group?

Cytosorbents (NASDAQ:CTSO) and Safe Pro Group (NASDAQ:SPAI) are both small-cap medical equipment companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends.

Cytosorbents has a beta of 1.35, suggesting that its share price is 35% more volatile than the broader market. Comparatively, Safe Pro Group has a beta of 3.28, suggesting that its share price is 228% more volatile than the broader market.

32.9% of Cytosorbents shares are owned by institutional investors. 7.8% of Cytosorbents shares are owned by company insiders. Comparatively, 54.8% of Safe Pro Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Cytosorbents has a net margin of -31.85% compared to Safe Pro Group's net margin of -800.91%. Safe Pro Group's return on equity of -119.17% beat Cytosorbents' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytosorbents	-31.85%	-235.57%	-37.88%
Safe Pro Group	-800.91%	-119.17%	-107.17%

Cytosorbents has higher revenue and earnings than Safe Pro Group. Safe Pro Group is trading at a lower price-to-earnings ratio than Cytosorbents, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytosorbents	$37.06M	0.63	-$8.20M	-$0.19	N/A
Safe Pro Group	$610K	141.78	-$14.32M	-$0.71	N/A

In the previous week, Safe Pro Group had 7 more articles in the media than Cytosorbents. MarketBeat recorded 8 mentions for Safe Pro Group and 1 mentions for Cytosorbents. Cytosorbents' average media sentiment score of 1.89 beat Safe Pro Group's score of 0.75 indicating that Cytosorbents is being referred to more favorably in the media.

Company	Overall Sentiment
Cytosorbents	Very Positive
Safe Pro Group	Positive

Cytosorbents presently has a consensus target price of $5.38, indicating a potential upside of 1,348.79%. Safe Pro Group has a consensus target price of $10.00, indicating a potential upside of 141.55%. Given Cytosorbents' higher possible upside, research analysts clearly believe Cytosorbents is more favorable than Safe Pro Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytosorbents	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Safe Pro Group	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.80

Summary

Cytosorbents beats Safe Pro Group on 9 of the 16 factors compared between the two stocks.

How does Cytosorbents compare to Inovio Pharmaceuticals?

Cytosorbents (NASDAQ:CTSO) and Inovio Pharmaceuticals (NASDAQ:INO) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, dividends, analyst recommendations, earnings, risk, profitability and valuation.

Cytosorbents presently has a consensus price target of $5.38, indicating a potential upside of 1,348.79%. Inovio Pharmaceuticals has a consensus price target of $4.25, indicating a potential upside of 284.62%. Given Cytosorbents' higher probable upside, equities research analysts clearly believe Cytosorbents is more favorable than Inovio Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytosorbents	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Inovio Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

32.9% of Cytosorbents shares are owned by institutional investors. Comparatively, 26.8% of Inovio Pharmaceuticals shares are owned by institutional investors. 7.8% of Cytosorbents shares are owned by company insiders. Comparatively, 1.7% of Inovio Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Cytosorbents has a beta of 1.35, indicating that its share price is 35% more volatile than the broader market. Comparatively, Inovio Pharmaceuticals has a beta of 1.49, indicating that its share price is 49% more volatile than the broader market.

Cytosorbents has higher revenue and earnings than Inovio Pharmaceuticals. Cytosorbents is trading at a lower price-to-earnings ratio than Inovio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytosorbents	$37.06M	0.63	-$8.20M	-$0.19	N/A
Inovio Pharmaceuticals	$60K	1,515.14	-$84.95M	-$1.45	N/A

Inovio Pharmaceuticals has a net margin of 0.00% compared to Cytosorbents' net margin of -31.85%. Cytosorbents' return on equity of -235.57% beat Inovio Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytosorbents	-31.85%	-235.57%	-37.88%
Inovio Pharmaceuticals	N/A	-489.79%	-95.40%

In the previous week, Inovio Pharmaceuticals had 2 more articles in the media than Cytosorbents. MarketBeat recorded 3 mentions for Inovio Pharmaceuticals and 1 mentions for Cytosorbents. Cytosorbents' average media sentiment score of 1.89 beat Inovio Pharmaceuticals' score of 0.63 indicating that Cytosorbents is being referred to more favorably in the media.

Company	Overall Sentiment
Cytosorbents	Very Positive
Inovio Pharmaceuticals	Positive

Summary

Cytosorbents beats Inovio Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

Get Cytosorbents News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CTSO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CTSO vs. The Competition

Export

Metric	Cytosorbents	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$23.31M	$8.44B	$6.84B	$12.34B
Dividend Yield	N/A	2.47%	2.67%	6.11%
P/E Ratio	-1.95	16.28	25.87	24.19
Price / Sales	0.63	5.64	553.99	100.49
Price / Cash	N/A	18.07	29.09	36.93
Price / Book	4.12	3.44	10.79	6.42
Net Income	-$8.20M	$226.25M	$3.58B	$337.00M
7 Day Performance	-10.17%	2.62%	2.49%	0.94%
1 Month Performance	-24.42%	-2.77%	0.21%	-0.66%
1 Year Performance	-69.84%	1.03%	35.20%	27.96%

Cytosorbents Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CTSO Cytosorbents	3.4152 of 5 stars	$0.37 +2.5%	$5.38 +1,348.8%	-70.6%	$23.31M	$37.06M	N/A	220	Positive News Gap Up
VANI Vivani Medical	3.4427 of 5 stars	$1.18 +4.4%	$3.75 +217.8%	-9.1%	$101.76M	N/A	N/A	20	Positive News Gap Up
LAKE Lakeland Industries	3.6312 of 5 stars	$10.21 +4.5%	$16.00 +56.7%	-18.1%	$100.77M	$192.65M	N/A	2,600	Analyst Downgrade
PYPD PolyPid	2.7373 of 5 stars	$4.99 -2.7%	$11.67 +133.8%	+33.1%	$95.21M	N/A	N/A	80	High Trading Volume
SPAI Safe Pro Group	2.9472 of 5 stars	$4.47 -4.1%	$10.00 +123.7%	+53.2%	$93.38M	$610K	N/A	11

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CTSO) was last updated on 6/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cytosorbents (CTSO) Competitors

CTSO vs. VANI, LAKE, PYPD, SPAI, and INO

How does Cytosorbents compare to Vivani Medical?

Summary

How does Cytosorbents compare to Lakeland Industries?

Summary

How does Cytosorbents compare to PolyPid?

Summary

How does Cytosorbents compare to Safe Pro Group?

Summary

How does Cytosorbents compare to Inovio Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTSO vs. The Competition

Cytosorbents Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cytosorbents (CTSO) Competitors

CTSO vs. VANI, LAKE, PYPD, SPAI, and INO

How does Cytosorbents compare to Vivani Medical?

Is CTSO or VANI more profitable?

Which has more risk and volatility, CTSO or VANI?

Do institutionals & insiders believe in CTSO or VANI?

Which has stronger earnings and valuation, CTSO or VANI?

Do analysts recommend CTSO or VANI?

Does the media prefer CTSO or VANI?

Summary

How does Cytosorbents compare to Lakeland Industries?

Which has stronger earnings and valuation, CTSO or LAKE?

Is CTSO or LAKE more profitable?

Do institutionals and insiders believe in CTSO or LAKE?

Do analysts recommend CTSO or LAKE?

Does the media refer more to CTSO or LAKE?

Which has more risk & volatility, CTSO or LAKE?

Summary

How does Cytosorbents compare to PolyPid?

Does the media prefer CTSO or PYPD?

Which has higher valuation & earnings, CTSO or PYPD?

Is CTSO or PYPD more profitable?

Do analysts recommend CTSO or PYPD?

Which has more volatility and risk, CTSO or PYPD?

Do insiders & institutionals believe in CTSO or PYPD?

Summary

How does Cytosorbents compare to Safe Pro Group?

Which has more risk and volatility, CTSO or SPAI?

Do institutionals & insiders believe in CTSO or SPAI?

Is CTSO or SPAI more profitable?

Which has stronger valuation and earnings, CTSO or SPAI?

Does the media prefer CTSO or SPAI?

Do analysts prefer CTSO or SPAI?

Summary

How does Cytosorbents compare to Inovio Pharmaceuticals?

Do analysts prefer CTSO or INO?

Do insiders & institutionals have more ownership in CTSO or INO?

Which has more volatility and risk, CTSO or INO?

Which has preferable valuation & earnings, CTSO or INO?

Is CTSO or INO more profitable?

Does the media refer more to CTSO or INO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTSO vs. The Competition

Cytosorbents Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools